Page 25 - Biocon

Biocon starts 'Ek Prayaas' nationwide awareness on Hepatitis C

As per WHO data, 130-150 mn people globally have chronic Hepatitis C infection, of which 15 mn are in India

Biocon: Positives factored in

The stock hit an all-time high and ended 15 per cent higher at Rs 808.70 on Friday

Biocon to launch insulin glargine in Malaysia in H2 FY 2016-17

Biocon has posted 17% rise in net profit at Rs 147 crore for the first quarter ended June 30

Biocon shares surge 10% post Q1 results

The stock soared 9.9 per cent to touch its one-year high level of Rs 771 at BSE

Biocon up over 5% post Q1 results, EMA review of Biosimilar

The stock surged 7% to Rs 749 after the company reported 35% YoY jump in its consolidated net profit of Rs 167 crore in Q1.

Biocon Q1 profit up 34.45% to Rs 166.6 cr

Biocon and Mylan apply for regulatory approval at EU for biosimilar of anti-cancer drug Pegfilgrastim

Biocon Q1 net up 17% at Rs 147 crore

The company's shares ended at Rs 701.50 apiece on the BSE

Biocon launches insulin Glargine in disposable pens in Japan

The Japanese Glargine market is estimated to be around $144 million, Biocon said in a statement

Biocon gains on launching Insulin Glargine in Japan

The stock was trading higher by 3% at Rs 732 on the National Stock Exchange at 09:27 AM.

Biosimilars: A shot in the arm for Biocon's future prescription

Its huge R&D spending on biosimilars, despite investor apathy, has started to show results

Biocon begins clinical trials for drug to treat rare eye disorder

The drug has been jointly developed with US-based QuarK Pharmaceuticals

Biocon, Quark get DCGI nod for trials of new eye disease drug

The companies also announced the randomisation of the first patient in India in the global Phase II/III study of the new drug candidate

Biocon hits new lifetime high

Since April 26, post March quarter results, the stock rallied 30% as compared to 3% rise in the S&P BSE Sensex

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Trastuzumab is indicated for treatment of a type of breast cancer, Biocon said

Yes Bank, BPCL, Biocon, Finolex Cables hit lifetime highs

HDFC Bank, Asian Paints, City Union Bank, Grasim Ind, IndusInd Bank, Pidilite Ind and Supreme Ind hit record highs

Biocon: Near-term positives priced in

Biosimilars in trial stages; once approved, these can lead to much larger gains

Biocon's Q4 net profit jumps 250% to Rs 361 crore on exceptional income

Amount of Rs 268 crore, allocated for research earlier, was shown as income after inking pact for rh insulin with Mexico-based firm

Biocon expects more filings this year for biosimilars, drugs

Q4 profit up 79% to Rs 361 crore; invests more on R&D

Street confidence rises on Biocon's insulin biosimilars

With expected filings of four insulin products in the current financial year, analysts have started upgrading their earnings estimates for the company

Biocon nears 52-week high on heavy volumes

The stock up 9% to Rs 533 on the BSE, trading close its 52-week high of Rs 544 touched on January 5.